Group 1 - The core viewpoint of the articles highlights the strong confidence of the company in its value and the industry outlook, as evidenced by its continuous share buyback actions totaling over 64 million HKD [1] - The company has repurchased approximately 560,000 shares at around 5.95 HKD per share on February 12, marking the 14th consecutive trading day of intensive buybacks [1] - The recent government meeting emphasized the broad prospects of "Artificial Intelligence+" which is expected to drive consumption and industrial upgrades, providing strong development momentum for the AI healthcare sector [1] Group 2 - The company has successfully entered the "Revealing the List" of the Ministry of Industry and Information Technology's 2025 AI medical device innovation tasks with a multimodal AI database project in collaboration with Tongji Hospital [2] - This inclusion reflects the company's strong capabilities in the AI medical field and aligns its business layout with national strategic needs, positioning it to seize opportunities in the commercialization wave of AI healthcare [2]
医渡科技(02158)连续14日回购累计超6400万港元，紧跟“人工智能+”战略拥抱行业风口